Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Y mAbs Therapeutics stock
Learn how to easily invest in Y mAbs Therapeutics stock.
Y mAbs Therapeutics is a biotechnology business based in the US. Y mAbs Therapeutics shares (YMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Y mAbs Therapeutics employs 148 staff and has a trailing 12-month revenue of around $39.8 million.
How to buy shares in Y mAbs Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – YMAB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Y mAbs Therapeutics stock price (NASDAQ: YMAB)Use our graph to track the performance of YMAB stocks over time.
Y mAbs Therapeutics shares at a glance
|Latest market close||$14.42|
|52-week range||$6.50 - $29.88|
|50-day moving average||$16.58|
|200-day moving average||$13.15|
|Wall St. target price||$28.33|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.68|
Buy Y mAbs Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Y mAbs Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Y mAbs Therapeutics price performance over time
|1 week (2022-09-23)||3.30%|
|1 month (2022-09-01)||-9.93%|
|3 months (2022-07-01)||-6.00%|
|6 months (2022-04-01)||10.41%|
|1 year (2021-10-01)||-50.80%|
|2 years (2020-10-01)||-63.80%|
|3 years (2019-10-01)||24.59|
|5 years (2017-09-27)||N/A|
Y mAbs Therapeutics financials
|Revenue TTM||$39.8 million|
|Gross profit TTM||$32.4 million|
|Return on assets TTM||-38.88%|
|Return on equity TTM||-73.8%|
|Market capitalisation||$610.3 million|
TTM: trailing 12 months
Y mAbs Therapeutics share dividends
We're not expecting Y mAbs Therapeutics to pay a dividend over the next 12 months.
Y mAbs Therapeutics share price volatility
Over the last 12 months, Y mAbs Therapeutics's shares have ranged in value from as little as $6.5 up to $29.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Y mAbs Therapeutics's is 1.116. This would suggest that Y mAbs Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Y mAbs Therapeutics overview
Y-mAbs Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc.
Y mAbs Therapeutics in the news
YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock?
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
Frequently asked questionsWhat percentage of Y mAbs Therapeutics is owned by insiders or institutions?
Currently 12.331% of Y mAbs Therapeutics shares are held by insiders and 68.192% by institutions. How many people work for Y mAbs Therapeutics?
Latest data suggests 148 work at Y mAbs Therapeutics. When does the fiscal year end for Y mAbs Therapeutics?
Y mAbs Therapeutics's fiscal year ends in December. Where is Y mAbs Therapeutics based?
Y mAbs Therapeutics's address is: 230 Park Avenue, New York, NY, United States, 10169 What is Y mAbs Therapeutics's ISIN number?
Y mAbs Therapeutics's international securities identification number is: US9842411095 What is Y mAbs Therapeutics's CUSIP number?
Y mAbs Therapeutics's Committee on Uniform Securities Identification Procedures number is: 984241109
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert